Compare Novo Nordisk A/S (NVO) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Simon Property Group Inc — how do they compare? Novo Nordisk A/S trades at $38.62 (market cap $165.31B), while Simon Property Group Inc trades at $199.42 (market cap $64.59B). The key difference: Novo Nordisk A/S is far larger — about 2.6× Simon Property Group Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Simon Property Group Inc for 99 Days on average.
| NVO | SPG | |
|---|---|---|
Market Cap | $165.31B | $64.59B |
Volume | 11,432,838 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $63.98 | $236.70 |
52-Week Low | $35.29 | $173.35 |
Typical Hold Time | 116 Days | 99 Days |
Enterprise Value | $179.56B | $93.03B |
Dividend Yield | 4.71% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
SPG trades at $199.42, up 0.93% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $6.36B in 2025 and a net income margin of 66.57%, though Q2 2026 EPS missed expectations. Recent news highlights leasing demand strength and a new media network launch, while analyst consensus is a $222.90 price target with 42% buy ratings.
Outlook is mixed: fundamentals are robust with high profitability and dividend yield, but technical weakness and net cash outflows pose risks. Investors may find value in the discounted valuation relative to targets, though sensitivity to interest rates and debt maturities requires caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
